Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls

Cited by (274)

Items 201–274 of 274

1. Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354
   Tayla A. Rees, Ben Buttle, Zoe Tasma, Sung-Hyun Yang, Paul W. R. Harris, Christopher S. Walker · 2024 · Frontiers in Pharmacology
2. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review 2019 – present
   Ghulam Abbas, M. S. Akhtar, Q. M. I. Haq, Issa Sulaiman Al-Amri, Daijie Wang, Hidayat Hussain · 2024 · Expert Opinion on Therapeutic Patents
3. Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
   Lalitha Vani Sundararaman, Divakara Gouda, Anil Kumar, Sumithra Sundararaman, Basavana Goudra · 2025 · Journal of Clinical Medicine
4. Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
   Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong‐Sik Ham, JW Kim, Kun‐Ho Yoon, Kyong Soo Park, Hye Seung Jung · 2015 · Islets
5. Role of growth factors in control of pancreatic beta cell mass
   Lynne L. Levitsky, Goli Ardestani, David B. Rhoads · 2014 · Current Opinion in Pediatrics
6. Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy
   Korytkowski, Mary T, Karslioglu French, Esra, Brooks, Maria, DeAlmeida, Dilhari, Kanter, Justin, Lombardero, Manuel, Magaji, Vasudev, Orchard, Trevor, Siminerio, Linda · 2016 · BMJ Open Diabetes Research & Care
7. Independent, but not co-supplementation, with nitrate and resveratrol improves glucose tolerance and reduces markers of cellular stress in high-fat-fed male mice
   Rachel M. Handy, Geneviève J. DesOrmeaux, Pierre‐Andre Barbeau, Sara M. Frangos, Graham P. Holloway · 2023 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
8. Optimizing clinical outcomes resulting from glucose‐lowering therapies in type 2 diabetes: increased confidence about the DPP ‐4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin
   Craig J. Currie, Sarah E. Holden · 2014 · Diabetes Obesity and Metabolism
9. Sweet taste receptor inhibitors: Potential treatment for equine insulin dysregulation
   Melody Anne de Laat, Murad H. Kheder, Christopher C. Pollitt, Martin N. Sillence · 2018 · PLoS ONE
10. Obesity
    Michael Alexander Cowley, Wendy A. Brown, Robert V. Considine · 2015 · Elsevier eBooks
11. Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway
    Yi‐Ching Liu, Yu‐Hsin Tseng, Yen-Hsien Wu, Lorraine Tong, Siao‐Ping Tsai, Shang‐En Huang, Bin‐Nan Wu, Shih‐Hsing Lo, I-Chen Chen, Zen‐Kong Dai et al. · 2024 · European Journal of Pharmacology
12. New insight on the role of liraglutide in alleviating dexamethasone-induced pancreatic cytotoxicity via improving redox status, autophagy flux, and PI3K/Akt/Nrf2 signaling
    Walaa Sayed Elseady, Rasha A. Abd Ellatif, Remon S. Estfanous, Marwa Nagy Emam, Walaa Arafa Keshk · 2021 · Canadian Journal of Physiology and Pharmacology
13. GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
    Jonathan P. Whitehead, Meng‐Wong Taing, Felicity J. Rose · 2014 · Drug Design Development and Therapy
14. Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions
    Rosaria Maddalena Ruggeri, Erika Maria Grossrubatscher, Eleonora Ciocca, Iderina Hasballa, Simona Jaafar, Monica Oldani, Manila Rubino, Flaminia Russo, Andrea Maria Isidori, Annamaria Anita Livia Colao et al. · 2025 · Reviews in Endocrine and Metabolic Disorders
15. Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway
    Yue Li, Rui Gao, Zhiyan Yang, Huiying Zong, Yan Li · 2024 · Life Sciences
16. Studying Pancreatic Risks Caused by Incretin-Based Therapies
    Michael Albrecht Nauck, Juris Jendrik Meier · 2014 · Journal of Diabetes Science and Technology
17. The equine glucose-dependent insulinotropic polypeptide receptor: A potential therapeutic target for insulin dysregulation
    Murad H. Kheder, Martin N. Sillence, L. M. Bryant, Melody Anne de Laat · 2017 · Journal of Animal Science
18. Tumor‐like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretin‐induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat
    Tomohide Hayami, Norihide Yokoi, Takuro Yamaguchi, Kohei Honda, Naoya Murao, Harumi Takahashi, Shujie Wang, Yusuke Seino, Hideki Kamiya, Daisuke Yabe et al. · 2020 · Journal of Diabetes Investigation
19. Chronic exposure to incretin metabolites GLP-1(9−36) and GIP(3−42) affect islet morphology and beta cell health in high fat fed mice
    Ananyaa Sridhar, Dawood Khan, Gayathri Babu, Nigel Irwin, Victor A. Gault, Peter R. Flatt, R. Charlotte Moffett · 2024 · Peptides
20. Pancreatic Hormones
    Pierre DE MEYTS, Pierre J. Lefèbvre · 2019 · Elsevier eBooks
21. Control of intestinal stem cell fate: A novel approach to treating diabetes
    Shunsuke Yamane, Nobuya Inagaki · 2015 · Journal of Diabetes Investigation
22. Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy
    Gladys Teitelman · 2014 · Endocrinology
23. Tuning to the right signal
    Mark O. Huising · 2015 · Diabetologia
24. Antidiabetika
    S. Offermanns · 2020 · Springer eBooks
25. GLP-1
    John A. Williams · 2014
26. The involvement of T1R family receptors expressed outside the oral cavity in the regulation of metabolism
    Vladimir O. Murovets, Egor A. Sozontov, Vasiliy A. Zolotarev · 2024 · Успехи физиологических наук
27. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)
    Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial, Yuichi Terawaki, Chikayo Iwaya, Takashi Nomiyama, Dai Shimono, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Toru Shigeoka, Nobuya Hamanoue, Ryoko Motonaga et al. · 2020 · Diabetology International
28. Sitagliptin
    Robert G. Bennett · 2018 · Elsevier eBooks
29. Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion
    Shenaz Khan, Robert J. Gaivin, Zhiyu Liu, Vincent Li, Ivy S. Samuels, Jinsook Son, Patrick Osei‐Owusu, Jeffrey Lawrence Garvin, Domenico Accili, Jeffrey R. Schelling · 2025 · Journal of Clinical Investigation
30. Exercise-Induced Pancreatic Islet Adaptations in Health and Disease
    Sabrina Grassiolli, Antonio Carlos Boschero, Everardo Magalhães Carneiro, Cláudio Cesar Zoppi · 2014 · Springer eBooks
31. An overview of non-insulin adjunctive therapies for Type 1 diabetes
    Chitrabhanu Ballav, Stephen C. L. Gough · 2014 · Diabetes Management
32. Pancreatic Islet Adaptation and Failure in Obesity and Diabetes
    Nicolai M. Doliba · 2015 · Springer eBooks
33. Stem cell-based approach in diabetes and pancreatic cancer management
    Demeng Chen, Yizhou Jiang · 2017 · Cancer translational medicine
34. Impact of incretin-related agents on endothelial cell function
    Hiroshi Nomoto, Hideaki Miyoshi, Akinobu Nakamura, Tatsuya Atsumi, Naoki Manda, Yoshio Kurihara, Shin Aoki, on behalf of SAIS Study Group · 2017 · Clinical Trials in Degenerative Diseases
35. Glucagon and the Glucagon-Like Peptides
    Daniel J. Drucker · 2015 · Elsevier eBooks
36. T1R taste receptors and the regulation of carbohydrate intake and metabolism in mammals
    Vladimir O. Murovets, Ekaterina A. Lukina · 2022 · Integrative Physiology
37. Methods for Assessing the In Vivo Role of PTEN in Glucose Homeostasis
    Cynthia T. Luk, Stephanie A. Schroer, Minna Woo · 2015 · Methods in molecular biology
38. Comment on Andersen et al, Pancreatitis–Diabetes–Pancreatic Cancer
    Alan Charles Moses, Lotte Bjerre Knudsen, Claus Bo Svendsen · 2014 · Pancreas
39. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action
    Marie Helene Schernthaner-Reiter, Guntram Schernthaner · 2016 · Expert Review of Endocrinology & Metabolism
40. Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
    Joachim Neumann, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs · 2026 · Pharmaceutics
41. Lentiviral GLP-1 gene therapy elicits developmental stage–dependent β-cell regeneration in diabetic rats
    Ezgi Erbasan, Melike Aliciaslan, Fulya Erendor, Sümeyye Şensoy, Busra Cetin, Mustafa Aydemir, Salih Şanlıoğlu · 2026 · Journal of Molecular Medicine
42. Метаболічні та психологічні рестрикти корекції харчування дітей із надлишковою масою тіла
    Tetyana Chaychenko, Natalja Georgievska · 2016 · CHILD`S HEALTH
43. Incretin-Based Therapies: Revisiting Their Mode of Action
    Brian Thomas Layden, Barton L. Wicksteed, Franck Mauvais‐Jarvis · 2017 · Endocrinology
44. In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?
    Jean Claude Reubi · 2017 · Journal of Nuclear Medicine
45. Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases
    Takako K. Abe, Miwako Nakanishi, Osami Watanabe, Hiroe Kawano, Hiroshi Bando · 2018 · Diabetes Research - Open Journal
46. Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
    Päivi Maria Paldánius · 2020 · Diabetes & Metabolism Journal
47. Exercise-Induced Pancreatic Islet Adaptations in Health and Disease
    Claudio Cesar Zoppi, GRASSIOL Sabrina, Boschero Antonio Carlos, Carneiro Everardo Magalhães · 2013 · Springer eBooks
48. Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
    Qi N. Cui · 2024 · JAMA Ophthalmology
49. A Probable Case of Tirzepatide-Induced Acute Pancreatitis
    Yovan Ram Kurrun Sumaruth, Rudramun Gopal, Faris Chater, Saurav Dhawan, Tamzin Wild · 2025 · Cureus
50. Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients
    Qiang Du, Yanjun Wang, Sheng Yang, Ping Han · 2015 · Patient Preference and Adherence
51. Future Drug Treatments for Type 1 Diabetes
    Jennifer L. Sherr, Eda Cengiz, Michelle Anne Van Name, STUART ALAN WEINZIMER, William V. Tamborlane · 2016 · Wiley eBooks
52. GLP-1 receptor – Do we really know what we’re looking at?
    Jan Homolak, Ana Babić Perhoč, Ana Knezović, Jelena Osmanović Barilar, Melita Šalković‐Petrišić · 2021 · Acta Histochemica
53. Liraglutide normalised glucose tolerance and the response of insulin to glucose in a non-obese patient with newly diagnosed type-2 diabetes mellitus
    Katsumi Iizuka, Hiroyuki Niwa, Youichi Takahashi, Jun Takeda · 2014 · Diabetology International
54. Cancers du pancréas et sécurité des incrétines : état des lieux en 2014
    S. Halimi · 2014 · Médecine des Maladies Métaboliques
55. Assessment of β-Cell Function
    Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch · 2014 · Springer eBooks
56. MicroRNAs and Long Non-Coding RNAs in Pancreatic Beta Cell Function
    MICHAEL D. WALKER · 2014 · Elsevier eBooks
57. Action of Incretins on the Pancreatic α Cell: Control of Glucagon Secretion
    Laura J. McCulloch, Mahdieh Godazgar, Patrik Rorsman, Reshma D. Ramracheya · 2015 · IMPERIAL COLLEGE PRESS eBooks
58. Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
    Masao Toyoda, Masaaki Miyauchi, Noriko Kaneyama, Moritsugu Kimura, Tomoya Umezono, Daisuke Suzuki, Masafumi Fukagawa · 2017 · Journal of Diabetes and Obesity
59. Acute Impaired Glucoregulation and Disrupted Gastrointestinal Hormone Secretion in Adolescents in Response to Caffeine-Containing and Nutritionally Fortified “Energy Shots”
    Heidi Virtanen · 2017 · Libraries and Cultural Resources (University of Calgary)
60. Modulation of the Pancreatic Hormone, Glucagon by the Gut Peptide, GLP-1: Controversies, Challenges and Future Directions
    Sam Stephen, Reshma D. Ramracheya · 2017 · Springer eBooks
61. The Role of Lipoxygenase and Interleukin-6 on Islet β-cell Oxidative Stress and Dysfunction
    Abass M. Conteh · 2019 · IUScholarWorks (Indiana University)
62. Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice
    Masakazu Koshibu, Yusaku Mori, Hideki Kushima, Munenori Hiromura, Kyoko Kohashi, Michishige Terasaki, Naoya Osaka, Tomoki Fujikawa, Tomoyasu Fukui, Tsutomu Hirano · 2019 · The Showa University Journal of Medical Sciences
63. Influence of various fat sources on the glucose, insulin and incretin concentration in healthy cats
    Hitomi Oda, Tomoko Hiramatsu, Akihiro Mori, Toshinori Sako · 2020
64. Pancreatic Islet Adaptation and Failure in Obesity and Diabetes
    Nicolai M. Doliba · 2017 · Springer eBooks
65. Pancreatic Islet Adaptation and Failure in Obesity and Diabetes
    Nicolai M. Doliba · 2016 · Springer eBooks
66. Antidiabetika
    S. Offermanns · 2016 · Springer-Lehrbuch
67. GLP-1
    John A. Williams · 2021
68. Energy Drinks; Impact of Use in Patients with Diabetes, Obesity, and/or other Cardiometabolic Spectrum Conditions.
    Heberth Moran, Alfredo Labrada, Bryan Grissett, Monica Chiang, Gabriel Ikponmosa Uwaifo · 2022 · Medical Research Archives
69. Body fat distribution and obesity
    Ioannis G. Lempesis · 2023
70. Respostas do treinamento combinado sobre marcadores inflamatórios, metabólicos, autofágicos e de remodelamento do tecido adiposo em diabéticos tipo 2 com excesso de peso
    Ivan Luiz Padilha Bonfante · 2019
71. Salt-grilled Salmon Ingestion before Cooked Rice Reduces Postprandial Plasma Glucose Levels in Young Healthy Subjects
    Kenji Yoshino · 2025 · The Japanese Journal of Nutrition and Dietetics
72. Distinct Gut Microbiome Profiles Underlying Cardiometabolic Risk Phenotypes in Individuals with Obesity
    Iveta Nedeva, Yavor S. Assyov, Veselka Duleva, Vera Karamfilova, Zdravko Asenov Kamenov, Julian Naydenov, Teodora Handjieva‐Darlenska, Venelin Dimitrov Denchev, Alexander Kolevski, Victoria Pencheva et al. · 2026 · Nutrients
73. Genome-wide cell type-specific and sex-specific transcriptional dysregulation in the islet of Langerhans underlies islet dysfunction in Down syndrome-related diabetes
    Cyrus R. Sethna, Maria Del Carmen Mendoza Niemes, Bayley J. Waters, Matthew R. Wagner, Jacob Smith, Sutichot D. Nimkulrat, Julia Lemanski, Nicolas G Pintozzi, Valentina Lo Sardo, Barak Blum · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
74. A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management
    Negin Kordi, Rezvan Kheirandish, Peyman Akraminia, Friedrich Jung, Sajad Karami · 2025 · Clinical Hemorheology and Microcirculation